利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.016 秒)

    Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors
    4.
    发明申请
    Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors 有权
    杂环取代的吡啶基苯并噻吩作为激酶抑制剂

    公开(公告)号：US20160102081A1

    公开(公告)日：2016-04-14

    申请号：US14511004

    申请日：2014-10-09

    申请人： Allergan, Inc.

    发明人： Sougato Boral ,  Thomas C. Malone ,  Shimiao Wang ,  Sandhya Rao ,  Rong Yang

    IPC分类号： C07D409/14 ,  C07D401/04 ,  C07D405/14

    CPC分类号： C07D409/14 ,  C07D401/04 ,  C07D405/14

    摘要： This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

    摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 4和X如本文所定义。 式I化合物可用作受体酪氨酸激酶（RTK）抑制剂，可用于治疗癌症，血管增生性疾病，纤维化病症，肾小球膜细胞增殖性疾病和代谢疾病等疾病。

    Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
    7.
    发明授权
    Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors 有权
    杂环取代的吡啶基苯并噻吩作为激酶抑制剂

    公开(公告)号：US09359336B2

    公开(公告)日：2016-06-07

    申请号：US14511004

    申请日：2014-10-09

    申请人： Allergan, Inc.

    发明人： Sougato Boral ,  Thomas C. Malone ,  Shimiao Wang ,  Sandhya Rao ,  Rong Yang

    IPC分类号： C07D409/14 ,  C07D405/14 ,  C07D401/04

    CPC分类号： C07D409/14 ,  C07D401/04 ,  C07D405/14

    摘要： This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

    摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 4和X如本文所定义。 式I化合物可用作受体酪氨酸激酶（RTK）抑制剂，可用于治疗癌症，血管增生性疾病，纤维化病症，肾小球膜细胞增殖性疾病和代谢疾病等疾病。

    PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
    8.
    发明申请
    PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 有权
    作为蛋白激酶抑制剂和血管内皮生长因子受体2的调节剂的吡啶并吡啶衍生物

    公开(公告)号：US20160102088A1

    公开(公告)日：2016-04-14

    申请号：US14511326

    申请日：2014-10-10

    申请人： Allergan, Inc.

    发明人： Julie A. Wurster ,  Thomas C. Malone ,  Clarence Eugene Hull, III ,  Sandhya Rao ,  Rong Yang ,  Richard Yee

    IPC分类号： C07D471/04

    CPC分类号： C07D471/04

    摘要： This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

    摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，其中X，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义。 式I化合物可用作蛋白激酶（PK）抑制剂，可用于治疗癌症，血管增生性疾病，纤维化病症，肾小球系膜细胞增生性疾病，代谢疾病炎症性疾病和神经变性疾病等疾病。